Olivier Robineau
Lille, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 123 publications
Emerging Risk for Human T-Cell Leukemia Virus Type 1 Transmission with HIV-Positive Breastfeeding Support.
Journal: Emerging infectious diseases
Published: June 28, 2026
Lenacapavir Use in France: A National, Observational Study (LENAddOn).
Journal: Open forum infectious diseases
Published: April 23, 2026
Mpox: clinical patterns and implications for epidemic management - a cohort study.
Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Published: March 04, 2026
Archived M184V/I Mutation and Risk of Virological Failure After Switching to Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate: A National Observational Study (Dat'AIDS Cohort).
Journal: Open forum infectious diseases
Published: February 26, 2026
Assessment of healthcare access and knowledge of HIV pre-exposure prophylaxis in women engaging in sex work: An exploratory study in Lille, Northern France.
Journal: Medicine
Published: December 26, 2025
Comparative Evaluation of the New HIV VIDAS® DUO AG/AB Assay With DUO Ultra on Well Characterized Participants From the HIV-1 Acute Infection French ANRS PRIMO Cohort.
Journal: Journal of medical virology
Published: December 18, 2025
Factors associated with loss to follow-up among people with HIV in France.
Journal: AIDS (London, England)
Published: December 05, 2025
Treatment durability, satisfaction and quality of life in virologically suppressed HIV-1 people switching to doravirine: Results from the French study DoraVIH.
Journal: HIV medicine
Published: December 01, 2025
Durability of Two-Drug Antiretroviral Regimens as Maintenance Therapy in People Living with HIV and Reasons for Switch to a Three-Drug Regimen: A Real-Life Cohort Study.
Journal: AIDS patient care and STDs
Published: November 10, 2025
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500 mg at days 1, 15 and 43 in bone and joint or cardiovascular infection.
Journal: The Journal of antimicrobial chemotherapy
Published: September 20, 2025
HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir.
Journal: Communications medicine
Published: September 17, 2025
Association between persistent symptoms and health-related quality of life in the post-COVID-19 condition: a cross-sectional survey in a nationally representative sample of French adults.
Journal: Health and quality of life outcomes
Published: August 19, 2025
Last Updated: 09/26/2026